Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma

Glofitamab in combination with gemcitabine, oxaliplatin and rituximab is currently in clinical development for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). DLBCL is a type of non-Hodgkin lymphoma. Most people with DLBCL first notice painless lumps, often in their neck, armpit, groin, or abdomen, or in testicles for men. These are enlarged lymph nodes. They usually grow quite quickly, over just a few weeks. Relapsed cancer refers to cancer that initially responded to treatment but then returned. Refractory cancer refers to cancer that did not respond to treatment. The prognosis for patients with relapsed or refractory DLBCL remains poor, so there is a need to develop additional treatment options.